ArticleClinical and translational medicine2026
Lysosomal protein transmembrane 5 protects against myocardial ischemia-reperfusion injury by promoting mitophagy via the NEDD4-LC3 axis.
Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMitophagy is essential for mitochondrial quality control during myocardial ischemia-reperfusion (I/R) injury. Lysosomal protein transmembrane 5 (LAPTM5) has been implicated in cardiovascular disease and autophagy, but its role in cardiac mitophagy remains unclear.
methodsLAPTM5 knockout mice and cardiomyocyte-targeted AAV9-cTnT-LAPTM5 were used to determine the role of LAPTM5 in myocardial I/R injury. Cardiomyocyte hypoxia/reoxygenation models, mt-Keima imaging, mitochondrial fractionation, LC3-mitochondrial colocalization, co-immunoprecipitation, molecular docking, site-directed mutagenesis, NEDD4 gain- and loss-of-function, and p62 ubiquitination assays were used to investigate the underlying mechanism. Depending on data distribution and group number, appropriate parametric or non-parametric statistics were applied together with correction for multiple testing.
resultsLAPTM5 expression progressively decreased following I/R or H/R stress. LAPTM5 deficiency aggravated myocardial injury, cardiac dysfunction, and mitochondrial structural and functional damage, whereas LAPTM5 overexpression attenuated these abnormalities. LAPTM5 promoted mitophagy by enhancing LC3 recruitment to mitochondria. Mechanistically, LAPTM5 recruited NEDD4 to mitochondria through its PY3 motif and facilitated NEDD4-LC3 complex formation. NEDD4 depletion abolished LAPTM5-mediated mitophagy and cytoprotection, whereas re-expression of NEDD4-WT, but not the E3-inactive NEDD4-CS mutant, restored these effects. NEDD4-WT also increased p62 ubiquitination. AAV9-mediated LAPTM5 re-expression reduced infarct size, improved cardiac function, and preserved mitochondrial integrity in LAPTM5-deficient hearts.
conclusionsLAPTM5 protects against myocardial I/R injury by promoting mitophagy through the NEDD4-LC3 axis. PY3-dependent recruitment of NEDD4 and its E3 ubiquitin ligase activity facilitate LC3-associated mitochondrial clearance, accompanied by enhanced p62 ubiquitination, thereby preserving mitochondrial homeostasis during reperfusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.